VRC
Home
Vaccine Research Center
Scientific Updates
SARS Vaccine Development
The Vaccine Research Center (VRC) contracted with Vical,
Inc. to manufacture a single closed, circular DNA plasmid
based vaccine encoding the S protein of SARS-CoV. VRC mouse
studies demonstrated that this vaccine induces T cell and
neutralizing antibody responses, as well as protective immunity.
A Phase I open-label clinical study to evaluate safety, tolerability,
and immune response was completed in May 2006. The study enrolled
10 healthy 18-50 years old subjects, and administered 4 mg
DNA vaccinations at three one month intervals. Interim study
results indicate that the vaccine is well tolerated, and immunogenicity
analysis of the stored samples is ongoing.
NIH press release - December 13, 2004
First
U.S. SARS Vaccine Trial Opens at NIH. The first human
trial of a vaccine designed to prevent SARS infection opened
today.
NIH
press release - March 31, 2004
NIAID
Vaccine Protects Against SARS Virus Infection in Mice.
An experimental vaccine prevents the SARS virus from replicating
in laboratory mice, according to a new report in the April
1 issue of "Nature".
|